This summary provides a technical overview of the maintenance results from the GALAXI-1 trial, recently published in The Lancet Gastroenterology & Hepatology.
TL;DR
The Phase 2 GALAXI-1 trial demonstrates that guselkumab, a selective IL-23 p19 subunit antagonist, provides durable clinical and endoscopic efficacy through 48 weeks in patients with moderately to severely active Crohn’s disease. Notably, the study utilized a "treat-through" design, showing that even some initial non-responders achieved clinical remission with continued treatment, all while maintaining a favorable safety profile.
What Problem Does This Paper Address?
Crohn’s disease (CD) is a chronic, debilitating inflammatory bowel disease. While several biological classes exist—including TNF antagonists, integrin antagonists, and IL-12/23 inhibitors—many patients either never respond (primary non-response) or lose response over time (secondary loss of response).
There is a critical need for therapies that offer higher "ceilings" of efficacy, particularly regarding mucosal healing (endoscopic remission), which is a strong predictor of long-term positive outcomes. Guselkumab is unique because it not only binds the p19 subunit of IL-23 with high affinity but also binds the CD64 receptor on inflammatory monocytes, potentially neutralizing IL-23 at its primary source within inflamed tissues.
Methods
GALAXI-1 was a Phase 2, randomized, double-blind, multicenter trial. The study employed a "treat-through" design, which differs from the "re-randomized" design common in many IBD trials. In a treat-through study, patients remain on their assigned induction therapy through the maintenance phase regardless of their early response, allowing researchers to observe "slow responders."
Treatment Arms: 1. Guselkumab 200→100 mg: 200 mg IV at weeks 0, 4, 8; then 100 mg SC every 8 weeks. 2. Guselkumab 600→200 mg: 600 mg IV at weeks 0, 4, 8; then 200 mg SC every 4 weeks. 3. Guselkumab 1200→200 mg: 1200 mg IV at weeks 0, 4, 8; then 200 mg SC every 4 weeks. 4. Ustekinumab (Reference): ~6 mg/kg IV induction, then 90 mg SC every 8 weeks. 5. Placebo: Induction placebo, with responders continuing placebo and non-responders crossing over to ustekinumab at week 12.
The primary efficacy analysis population included 309 patients, stratified by baseline disease activity and prior biologic failure.
Datasets
The study analyzed data from 309 patients in the primary efficacy analysis population and 360 patients in the safety population. The cohort was diverse:
- Biologic-naive: 112 patients.
- Biologic-experienced: 197 patients (a "difficult-to-treat" group).
- Geography: 128 centers globally.
Key Insights and Ideas
- The Value of Persistence: A key "aha moment" came from the treat-through design. Among patients who did not have a clinical response to guselkumab at week 12, nearly half (46%) achieved a clinical response by week 24, and 41% were in clinical remission by week 48. This suggests that for some patients, the standard 12-week induction window may be too short to judge a drug's ultimate success.
- Deep Healing: Guselkumab showed impressive rates of endoscopic remission (SES-CD score ≤2). At week 48, up to 33% of patients in the highest dose group achieved endoscopic remission, compared to only 6% in the ustekinumab reference group (though the study wasn't powered for formal comparison).
- Mechanistic Synergy: The authors hypothesize that guselkumab’s dual binding (IL-23 p19 and CD64) may enrich the drug's presence in the inflamed microenvironment, contributing to the observed mucosal healing.
Key Results
- Clinical Remission (CDAI <150): At week 48, remission rates were 64%, 73%, and 57% across the three guselkumab groups, respectively.
- Endoscopic Response (≥50% improvement): Rates were 44%, 46%, and 44% for the guselkumab groups, compared to 30% for the ustekinumab reference group.
- Safety: Guselkumab was well-tolerated. The most common adverse events were nasopharyngitis and upper respiratory infections. No cases of active tuberculosis, opportunistic infections, or deaths occurred through week 48.
- Bio-Experienced Success: Even in patients who had failed prior biologics, guselkumab maintained high rates of clinical remission and endoscopic response.
Limitations and Future Work
- Phase 2 Constraints: As a Phase 2 study, it was not powered to perform formal statistical comparisons between the different guselkumab doses or against the ustekinumab reference arm.
- Placebo Comparison: Because most placebo non-responders crossed over to active treatment at week 12, the long-term placebo "maintenance" group was very small (n=15), limiting the ability to draw comparative conclusions at week 48.
- Phase 3 Transition: These results served as the foundation for the ongoing Phase 3 GALAXI-2 and GALAXI-3 trials, which will provide the definitive evidence required for regulatory approval and broader clinical use.
Summary updated